Why did CVS.DE stock drop today?

CVS.DE stock fell on 28 Jan 2026 after reports the government may keep Medicare Advantage rates roughly flat, which lowers expected revenue for benefits and PBM segments and prompted investor selling.

What is Meyka AI's view and grade for CVS.DE stock?

Meyka AI rates CVS.DE with a score out of 100: 67.76 (Grade B, HOLD). The grade balances cash flow strength against high leverage and margin pressure; grades are model outputs and not investment advice.

What price levels should traders watch for CVS.DE stock?

Key levels: immediate support **€61.34**, 200-day average **€62.17**, 50-day average **€67.76**, and model one-year forecast **€72.70**. A clear break below **€61.00** raises risk toward the year low **€50.05**.

How does the Medicare-rate news affect CVS.DE earnings and outlook?

Flat Medicare Advantage rates would weigh on the Health Care Benefits segment and could reduce guidance; that prospect drove the Jan 28 move and increases uncertainty ahead of 10 Feb 2026 earnings.

DE Stocks

Pre-market: CVS.DE (CVS Health) down 11.99% to €61.34 on XETRA 28 Jan 2026: Medicare-rate risk pressures outlook

ByDanny Kontos January 28, 2026January 28, 2026

CVS.DE stock slid 11.99% pre-market to €61.34 on XETRA on 28 Jan 2026 after headlines pointed to a proposed flat Medicare Advantage rate, which markets view as a revenue headwind for large insurers and PBMs. The move followed an open at €64.84 versus a previous close of €69.70, and came on light volume of 2,245 shares. We review drivers, valuation, technical levels and Meyka AI model forecasts to explain why the drop makes CVS.DE stock one of today’s top losers and what traders should watch next.